The Anorexia Nervosa drugs in development market research report provides comprehensive information on the therapeutics under development for Anorexia Nervosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anorexia Nervosa. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Anorexia Nervosa - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anorexia Nervosa and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Anorexia Nervosa by ten companies/universities/institutes. The top development phase for Anorexia Nervosa is preclinical with four drugs in that stage. The Anorexia Nervosa pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Anorexia Nervosa pipeline products market are: Pfizer, Biomind Labs and IntelGenx.

The key targets in the Anorexia Nervosa pipeline products market include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A), 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A), and Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1).

The key mechanisms of action in the Anorexia Nervosa pipeline product include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Agonist with three drugs in Phase II. The Anorexia Nervosa pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Anorexia Nervosa pipeline products market including Small Molecule, and Peptide.

Anorexia Nervosa overview

Anorexia nervosa is an eating disorder defined by restriction of energy intake relative to requirements, leading to a significantly low body weight. Patients will have an intense fear of gaining weight and distorted body image with the inability to recognize the seriousness of their significantly low body weight.

For a complete picture of Anorexia Nervosa’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.